(Q34614515)

3 August 2017

1 reference

title

Pharmacological interventions in aging and age-associated disorders: potentials of propargylamines for human use. (English)

1 reference

3 August 2017

Kenichi Kitani

1

1 reference

3 August 2017

Chiyoko Minami

2

1 reference

3 August 2017

Takako Yamamoto

3

1 reference

3 August 2017

Setsuko Kanai

4

1 reference

3 August 2017

Gwen O Ivy

5

1 reference

3 August 2017

Maria-Cristina Carrillo

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Annals of the New York Academy of Sciences

3 August 2017

published in

1 reference

3 August 2017

volume

959

1 reference

3 August 2017

page(s)

295-307

1 reference

Free-radical theory of aging. Increasing the functional life span

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Aging and oxidative stress: modulation by dietary restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Long-term treatment of male F344 rats with deprenyl: assessment of effects on longevity, behavior, and brain function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

L-deprenyl treatment in aged mice slightly increases life spans, and greatly reduces fecundity by aged males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

(-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

The ability of (-)deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

The effect of a long term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Long term treatment with (-)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

(-)Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Trophic effects of selegiline on cultured dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

L-deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Mortality in people taking selegiline: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2002.TB02101.X

10.1111/J.1749-6632.2002.TB02101.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference